Literature DB >> 15293097

Improvement of skin sclerosis after occurrence of anticentromere antibody in a patient with diffuse cutaneous systemic sclerosis.

Ikuko Hayakawa1, Shinichi Sato, Takeshi Echigo, Fumiaki Shirasaki, Minoru Hasegawa, Kazuhiko Takehara.   

Abstract

A 38-year-old woman had noticed sclerodactylia and Raynaud's phenomenon 10 months before consultation. She was diagnosed as having systemic sclerosis (SSc) based on the skin sclerosis of her arms, chest, and face. Antinuclear antibody (ANA) level was 1:1280 with a speckled pattern, but specific autoantibodies were negative. Following the treatment with oral prednisolone and D-penicillamine, her skin sclerosis gradually improved. Three months after initiation of prednisolone, she presented Pneumocystis carinii pneumonia. About 1 year after the first admission, the pattern of indirect immunofluorescence staining changed from the speckled pattern to the discrete speckled pattern, and simultaneously anticentromere antibody (ACA) was detected by enzyme-linked immunosorbent assay. Her skin sclerosis rapidly and remarkably improved after appearance of ACA. It is generally considered that once certain SSc-specific autoantibody occurs, it does not disappear and change into other specificity of autoantibody thereafter. This case suggests that the presence of ACA closely correlates with clinical features and also suggests that clinical features may change during the clinical course with the appearance of another specific ANA. This case is very rare because such a case was not reported previously.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293097     DOI: 10.1007/s10067-004-0876-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

Review 1.  The role of infectious agents in the pathogenesis of systemic sclerosis.

Authors:  Damir Hamamdzic; Laura M Kasman; E Carwile LeRoy
Journal:  Curr Opin Rheumatol       Date:  2002-11       Impact factor: 5.006

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Clinical significance of antinuclear antibodies in Japanese patients with systemic sclerosis.

Authors:  A Igarashi; K Takehara; Y Soma; K Kikuchi; Y Ishibashi
Journal:  Dermatologica       Date:  1990

4.  Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality.

Authors:  M M Ward; F Donald
Journal:  Arthritis Rheum       Date:  1999-04

5.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

Authors:  V D Steen; D L Powell; T A Medsger
Journal:  Arthritis Rheum       Date:  1988-02

6.  Pneumocystis carinii pneumonia in patients with connective tissue disease.

Authors:  V Chechani; A Bridges
Journal:  Chest       Date:  1992-02       Impact factor: 9.410

7.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.

Authors:  E M Tan; G P Rodnan; I Garcia; Y Moroi; M J Fritzler; C Peebles
Journal:  Arthritis Rheum       Date:  1980-06

8.  D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.

Authors:  V D Steen; T A Medsger; G P Rodnan
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

  8 in total
  2 in total

1.  Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis.

Authors:  Alessandro Volpe; Orazio Ruzzenente; Paola Caramaschi; Sara Pieropan; Ilaria Tinazzi; Antonio Carletto; Lisa Maria Bambara; Domenico Biasi
Journal:  Rheumatol Int       Date:  2009-02-05       Impact factor: 2.631

Review 2.  Abnormal B lymphocyte activation and function in systemic sclerosis.

Authors:  Ayumi Yoshizaki; Shinichi Sato
Journal:  Ann Dermatol       Date:  2015-02-03       Impact factor: 1.444

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.